/* Style Definitions */ table.MsoNormalTable {mso-style-name:"Table Normal"; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0; mso-style-noshow:yes; mso-style-priority:99; mso-style-parent:""; mso-padding-alt:0in 5.4pt 0in 5.4pt; mso-para-margin:0in; mso-para-margin-bottom:.0001pt; mso-pagination:widow-orphan; font-size:10.0pt; font-family:"Times New Roman","serif";} Dr. Alberta Leon is the principal investigator of this study. She hold a major in biochemistry at McGill University, Montreal,Canada, she graduated in biological sciences at the University of Padua. She has been director of the neuroscience laboratory of Fidia Farmaceutici, Abano Terme, Padova. In 1996, together with a group of professionals with experience in private as well as public and academic research institutions, she founded Research & Innovation (R&I), a private laboratory active in neuroscientific research. R&I includes a unit of medical diagnostics, providing genetic analyses to private medical centers and healthcare institutions. Dr. Leon is the current CEO and scientific director of R&I. She is also president and charter member of the “Antonio Cananzi Foundation for Headache and Cerebrovascular Diseases.” Her contribution to research on neurodegenerative and neuroinflammatory diseases has resulted in more than 140 scientific publications in peer-reviewed international journals.
Associated Grants
-
Trace Amines and Their Metabolites as Potential Heraldic Markers in Parkinson’s Disease
2012